HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
INSIDE INDUSTRY
Xylonix collaborates with BioGemex to develop novel pre-treatment point-of-care diagnostic
XDX-01, a novel, point-of-care pre-treatment diagnostic, has completed early validation studies, predicting patient responses (PFS, ORR) to cancer immunotherapies.

Xylonix (Xylonix.io), an immuno-oncology biotech, announced in August 2019 that it has signed a Memorandum of Understanding (MOU) with BioGemex, a leading Korean medical diagnostic company, to jointly develop a new pre-treatment point-of-care diagnostic, XDX-01, to better predict a patient’s response to T-cell mediated cancer immunotherapies in solid tumours.

T-cell mediated cancer immunotherapies such as PD-1 and PD-L1 inhibitors are increasingly becoming first line treatments in the treatment of solid cancer. While these breakthrough cancer treatments offer curative benefits in some patients, major challenges remain due to the high costs of treatment and low and unpredictable patient responses, leading to difficult issues surrounding insurance coverage and drug pricing policies for reimbursements by many governments.

Developed by Xylonix during its own immuno-oncology drug trial design optimization, the XDX-01 serum biomarker has demonstrated applicability in predicting the patient response and survival post PD-1 inhibitor treatments, with the prediction accountability of 88 percent and 79 percent for Objective Response Rate (ORR) and Progression-Free Survival (PFS), respectively, in site-agnostic manner. The current standard predictive biomarker, TMB, was shown to perform at 70 percent and 46 percent, respectively. XDX-01 will be developed as a cartridge-based modular system on an FDA-approved point-of-care reader device.

Dr. Jinhyuk Chung, Founder and Chief Scientific Officer of Xylonix, commented: “We are delighted to sign the MOU with BioGemex, their diagnostic manufacturing capabilities and expertise will be valuable to Xylonix as we accelerate the development of XDX-01 following our successful preliminary studies. We believe that XDX-01, our tumor microenvironment biomarker, has the potential to transform the cancer treatment decision pathway for patients with solid tumours. The rising costs of cancer treatment remains a pressing global issue, but physicians, pharmaceutical companies and payors are yet to find a reliable tool to ensure that the right patients get the right treatments. We believe that XDX-01 has the potential to be the right decision support tool.”

Xylonix and BioGemex will work together to jointly scale the manufacturing of XDX-01 and conduct broader clinical validation studies in anticipation of a commercial launch in H2 2020.

Today in the US, the average cost of cancer immunotherapies is approximately US$150,000 per year per patient to use, and it has been reported to fail in 85 percent of the prescribed patients in delivering any benefits.

 

Click here for the complete issue.

NEWS CRUNCH  
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy